A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepin Intravenous Infusion in COVID-19 Pneumonia Patients
Latest Information Update: 18 May 2022
Price :
$35 *
At a glance
- Drugs NuSepin (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- Sponsors Shaperon
- 27 Jan 2022 Status changed from recruiting to completed.
- 15 Mar 2021 Planned End Date changed from 30 Nov 2020 to 30 Apr 2021.
- 15 Mar 2021 Planned primary completion date changed from 30 Nov 2020 to 30 Apr 2021.